Small Lymphocytic Lymphoma
📧 Sign up to get email alerts when something new happens for Small Lymphocytic Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-03-31Clinical Trial Update: Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL [Phase 2]
Phase 2 trial evaluating zanubrutinib followed by zanubrutinib plus FCR/BR in newly diagnosed symptomatic CLL/SLL.
-
CLINICAL_TRIALS trial_result · 2022-03-28Clinical Trial Update: A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) [Phase 3]
This Phase 3 clinical trial update reports results for frontline therapy in chronic lymphocytic leukemia/small lymphocytic lymphoma comparin…
-
CLINICAL_TRIALS trial_result · 2022-03-28Clinical Trial Update: A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) [Phase 3]
Phase 3 trial evaluating ibrutinib plus venetoclax versus chlorambucil plus obinutuzumab as first-line therapy in chronic lymphocytic leukem…
-
FDA approval · 2022-03-10FDA Approved: ZYDELIG — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for ZYDELIG (idelalisib) from Gilead Sciences, Inc. The action updates the labeling for the drug…
-
CLINICAL_TRIALS trial_result · 2022-02-18Clinical Trial Update: Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL) [Phase 2]
Phase 2 study evaluating the combination of ibrutinib and venetoclax in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymph…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2021-12-17FDA Approved: COPIKTRA — Supplemental Application (Secura Bio, Inc)
The FDA has approved a supplemental application for COPIKTRA (duvelisib) by Secura Bio, Inc.
-
CLINICAL_TRIALS trial_result · 2021-12-15Clinical Trial Update: Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I) [Phase 2]
Phase 2 trial assessing SHINGRIX vaccine response in chronic lymphocytic leukemia patients, including those treated with BTK inhibitors; stu…
-
FDA approval · 2021-12-02FDA Approved: RITUXAN — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for Rituxan (rituximab) filed by Genentech, Inc., resulting in updated labeling for the product.
-
CLINICAL_TRIALS trial_result · 2021-12-02Clinical Trial Update: Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL [Phase 2]
Phase 2 trial evaluating consolidative therapy with ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphoc…
-
FDA approval · 2021-10-14FDA Approved: LENALIDOMIDE — Original Application (Dr. Reddy's Laboratories Inc.)
The FDA approved Dr. Reddy's Laboratories' original application for lenalidomide (generic), authorizing a generic version of the cancer drug…
-
CLINICAL_TRIALS trial_result · 2021-09-29Clinical Trial Update: Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma [Phase 2]
Phase 2 trial evaluating lenalidomide in combination with rituximab for various stage III/IV indolent non-Hodgkin lymphoma subtypes; study c…
-
CLINICAL_TRIALS trial_result · 2021-09-29Clinical Trial Update: Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL [Phase 2]
Phase 2 trial evaluating venetoclax plus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic ly…
-
CLINICAL_TRIALS trial_result · 2021-09-20Clinical Trial Update: A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [Phase 1, Phase 2]
Phase 1/2 open-label dose-finding trial evaluating CC-122 in combination with ibrutinib and obinutuzumab for chronic lymphocytic leukemia/sm…
-
FDA approval · 2021-08-31FDA Approved: REVLIMID — Supplemental Application (Celgene Corporation)
The FDA approved a supplemental application for REVLIMID (lenalidomide) submitted by Celgene Corporation. The action expands or updates the …
-
CLINICAL_TRIALS trial_result · 2021-08-18Clinical Trial Update: Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL [Phase 2]
Phase 2 trial evaluating acalabrutinib in patients with relapsed/refractory and treatment-naïve deletion 17p chronic lymphocytic leukemia/sm…
-
FDA approval · 2021-08-05FDA Approved: LENALIDOMIDE — Supplemental Application (Teva Pharmaceuticals, Inc.)
FDA approved a supplemental application for lenalidomide by Teva Pharmaceuticals, approving changes related to the drug's use.
-
CLINICAL_TRIALS trial_result · 2021-08-02Clinical Trial Update: Study Evaluating Venetoclax in Subjects With Hematological Malignancies [Phase 1, Phase 2]
Clinical trial update for venetoclax in hematological malignancies at phases 1 and 2; study status completed.
-
CLINICAL_TRIALS trial_result · 2021-05-07Clinical Trial Update: Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell [Phase 1]
Phase 1 study updating on CAR-20/19-T cells in relapsed/refractory B-cell lymphomas; results posted after completion.
-
CLINICAL_TRIALS trial_result · 2021-04-21Clinical Trial Update: Ruxolitinib Phosphate in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [Phase 2]
Phase 2 trial evaluating ruxolitinib phosphate in previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma has completed…
-
CLINICAL_TRIALS trial_result · 2021-03-19Clinical Trial Update: Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL) [Phase 1]
Phase 1 trial in Japanese participants assessing safety, tolerability, and pharmacokinetics of idelalisib in relapsed or refractory indolent…
-
CLINICAL_TRIALS withdrawal · 2021-03-17Clinical Trial Update: A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) [Phase 3]
Phase 3 trial BRAVURA evaluating duvelisib with rituximab and bendamustine versus placebo in indolent non-Hodgkin lymphoma was withdrawn.
-
CLINICAL_TRIALS trial_result · 2021-02-02Clinical Trial Update: Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL [Phase 1, Phase 2]
Phase 1/2 study of TP-0903 (AXL inhibitor) in previously treated chronic lymphocytic leukemia was terminated with results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-01-19Clinical Trial Update: Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis [Phase 2]
Phase 2 trial evaluating lenalidomide to enhance immune response to vaccine therapy in patients with chronic lymphocytic leukemia, small lym…
-
FDA approval · 2020-12-17FDA Approved: RIABNI — Original Application (Amgen, Inc)
FDA approved RIABNI (rituximab-arrx) from Amgen as a biosimilar to rituximab via Original Application.
-
CLINICAL_TRIALS trial_result · 2020-11-04Clinical Trial Update: Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) [Phase 2]
Phase 2 trial evaluating Ofatumumab in combination with methylprednisolone or with lenalidomide in relapsed/refractory CLL/SLL has completed…